Interview: Patrice Carayon – CEO, Chiesi France
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
Chiesi is an international company based in Parma, with 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas.With a turnover of more than €1.3 billion sales, Chiesi is among the top 50 pharmaceutical companies in the world. They have production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil) and R&D centres in Parma (Italy), Paris (France), Rockville (USA), Chippenham (UK).
Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to accompany its commercial activities. In 2013 Chiesi announced an investment of 22 million euros (USD 23.90 million) in their production site in Blois. Significant investments in manufacturing capacity have been made. Previously, the site employed 60 people, by the end of 2016 this number will have almost doubled.
Chiesi was established in France in 1992 through its subsidiary ProMedica. In 1999, the Italian group strengthened its presence with the acquisition of Logeais Group. Today, the French subsidiary is directed by Patrice Carayon. It represents 8 percent of total Group sales with a turnover of 104 million euros in 2014. Subsidiary of primary importance, France is Chiesi´s fifth most important market.
Contact
Address: Immeuble le Doublon – 11 Avenue Dubonnet, 92400 Courbevoie – France
Tel: 33 1 47688899
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
The basis of the pharmaceutical business model is changing. Take sales forces for instance, what will be the composition and daily routine? How much mixed media will it require? Currently,…
Emmanuelle Ribot-Mariotte, general manager of Alfa Wassermann Pharma France, reveals how over the past year the company has been working hard on a new innovative treatment for hepatic encephalopathy, Rifaximin-alpha…
Finding success in the shadows of Big Pharma and large research facilities, CleveXel serves as a bridge in the industry, specializing on selecting promising molecules for investment, and developing them…
Prof. Thierry Philip, President of Institut Curie, is proud of the model that the institute is thriving for: excellent science and research in all forms, from the most basic to…
The recently appointed general manager of Galderma France, reveals the company’s ambitious objective for the next ten years: to increase sales from two to ten billion Euros (2.18 billion USD to…
Eric Goupil reveals how the global CMO market has expanded considerably over recent years, with a move towards a more strategic mind-set in the pharmaceutical industry. Unither´s business model is…
The presence in France of Swiss medical compression garment manufacturer Sigvaris dates back more than 100 years. The current president, Alain Bertheas, describes the company’s history and explains its garments.…
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
A leading consultant to IMS and Professor at Paris Dauphine University reveals how the French healthcare system is moving in two main strategic directions: increasingly relying on private funding through…
Arnaud Pradel, Product Development Director and Co-Segment Leader of HORIBA Medical reveals how HORIBA has over 30 years of experience when it comes to launching products in the vitro diagnostic…
The president of the family-run Laboratoires Panpharma, a specialist in injectable drugs for the hospital sector, reveals how they have affiliates in both France and Germany, are in the process of…
Philippe Luscan reveals how Sanofi contributes almost USD 6.35 billion net to the French economy; how their five new global business units will drive future growth, and why they are…
Christian Deleuze reveals the impact of the acquisition by Sanofi in 2011; explains the profitability and global reach of the bio manufacturing facility in Lyon; and tells us that the current system…
See our Cookie Privacy Policy Here
